The FEMTELLE uPA/PAI-1 ELISA Test assess the likelihood of breast cancer reappearance in women with newly diagnosed, node-negative breast cancer. The test has been validated in multiple independent long-term clinical studies with more than 8000 patients.
» FEMTELLE allows to identify patients with high (uPA and/or PAI-1 high) and low (uPA and PAI-1 low) risk of recurrence.
» uPA und PAI-1 are the only new prognostic factors which are recommended at the highest level of evidence (LOE-1) for therapy decision in node-negative breast cancer by the German Guidelines for Diagnosis and Treatment of breast cancer.
» The test system is suitable for routine testing and clinical use.
» Its high reproducibility has been demonstrated in the prospective evaluation of an International Quality Assurance program.